NASDAQ:CNCE Concert Pharmaceuticals - CNCE Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Concert Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $8.34 -0.01 (-0.12%) (As of 01/31/2023 12:00 AM ET) Add Compare Share Share Today's Range$8.32▼$8.3750-Day Range$4.34▼$8.3952-Week Range$2.57▼$8.44Volume657,649 shsAverage Volume4.09 million shsMarket Capitalization$399.82 millionP/E RatioN/ADividend YieldN/APrice Target$19.67 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Concert Pharmaceuticals MarketRank™ ForecastAnalyst RatingHold2.20 Rating ScoreUpside/Downside135.8% Upside$19.67 Price TargetShort InterestHealthy4.53% of Shares Sold ShortDividend StrengthN/ASustainability-0.93Upright™ Environmental ScoreNews Sentiment0.28Based on 4 Articles This WeekInsider TradingSelling Shares$269,008 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($2.70) to ($2.13) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.53 out of 5 starsMedical Sector109th out of 1,055 stocksPharmaceutical Preparations Industry42nd out of 518 stocks 3.1 Analyst's Opinion Consensus RatingConcert Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.20, and is based on 1 buy rating, 4 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $19.67, Concert Pharmaceuticals has a forecasted upside of 135.8% from its current price of $8.34.Amount of Analyst CoverageConcert Pharmaceuticals has only been the subject of 4 research reports in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted4.53% of the outstanding shares of Concert Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverConcert Pharmaceuticals has a short interest ratio ("days to cover") of 1.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Concert Pharmaceuticals has recently decreased by 0.91%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldConcert Pharmaceuticals does not currently pay a dividend.Dividend GrowthConcert Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreConcert Pharmaceuticals has received a 69.07% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is driven by its "Clinical research services for physiological diseases " and "Basic medical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for Concert Pharmaceuticals is -0.93. Previous Next 2.9 News and Social Media Coverage News SentimentConcert Pharmaceuticals has a news sentiment score of 0.28. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.73 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Concert Pharmaceuticals this week, compared to 2 articles on an average week.Search Interest9 people have searched for CNCE on MarketBeat in the last 30 days. This is an increase of 800% compared to the previous 30 days.MarketBeat Follows5 people have added Concert Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 25% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Concert Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $269,008.00 in company stock.Percentage Held by Insiders11.33% of the stock of Concert Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions70.63% of the stock of Concert Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Concert Pharmaceuticals are expected to grow in the coming year, from ($2.70) to ($2.13) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Concert Pharmaceuticals is -2.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Concert Pharmaceuticals is -2.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioConcert Pharmaceuticals has a P/B Ratio of 2.57. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Concert Pharmaceuticals (NASDAQ:CNCE) StockConcert Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which discovers and develops novel small molecule drugs through the use of deuterium technology. Its product candidates target a range of diseases including autoimmune disorders, inflammation, and central nervous system disorders. The company was founded by Richard H. Aldrich, Roger D. Tung and Christoph H. Westphal on April 12, 2006 and is headquartered in Lexington, MA.Read More Receive CNCE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Concert Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address CNCE Stock News HeadlinesJanuary 30, 2023 | benzinga.comMoore Kuehn Encourages KERN, CNCE, AQUA and ANGN Investors to Contact Law FirmJanuary 24, 2023 | americanbankingnews.comShort Interest in Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) Increases By 10.1%February 1, 2023 | Investor Place Media (Ad)Cash Holders STILL Aren't Taking Steps to PrepareStocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.January 24, 2023 | americanbankingnews.comConcert Pharmaceuticals, Inc. (NASDAQ:CNCE) Receives $17.00 Consensus Price Target from BrokeragesJanuary 24, 2023 | americanbankingnews.comResearch Analysts Issue Forecasts for Concert Pharmaceuticals, Inc.'s FY2027 Earnings (NASDAQ:CNCE)January 23, 2023 | finance.yahoo.comConcert (CNCE) Stock Up 17% Last Week on Sun Pharma Buyout OfferJanuary 23, 2023 | americanbankingnews.comStockNews.com Lowers Concert Pharmaceuticals (NASDAQ:CNCE) to SellJanuary 22, 2023 | msn.com5 big deal reports: Sun Pharma’s $576M pact for Concert PharmaFebruary 1, 2023 | Investor Place Media (Ad)Cash Holders STILL Aren't Taking Steps to PrepareStocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.January 22, 2023 | americanbankingnews.comConcert Pharmaceuticals (NASDAQ:CNCE) Stock Rating Lowered by Truist FinancialJanuary 22, 2023 | americanbankingnews.comJefferies Financial Group Lowers Concert Pharmaceuticals (NASDAQ:CNCE) to HoldJanuary 20, 2023 | finance.yahoo.comWhy Concert Pharmaceuticals Stock Rocketed Higher This WeekJanuary 20, 2023 | marketwatch.comCNCE Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Concert Pharmaceuticals, Inc. Is Fair to ShareholdersJanuary 19, 2023 | benzinga.comSHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Concert Pharmaceuticals, Inc. (CNCE)January 19, 2023 | benzinga.comShareholder Alert: Ademi LLP investigates whether Concert Pharmaceuticals, Inc. has obtained a Fair Price in its transaction with Sun PharmaJanuary 19, 2023 | marketwatch.comConcert Pharmaceuticals Shares Rally on Takeover by Sun >CNCEJanuary 19, 2023 | wsj.comSHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Concert Pharmaceuticals, Inc. BuyoutJanuary 19, 2023 | finance.yahoo.comIndia-Based Sun Pharma Scoops Up Concert Pharmaceuticals For $576M Plus MilestonesJanuary 19, 2023 | finance.yahoo.comPharma giant in India buys Concert Pharmaceuticals in $576M dealJanuary 19, 2023 | marketwatch.comSun Pharmaceutical to Buy Concert Pharmaceuticals For Initial $576 Million >CNCEJanuary 19, 2023 | finance.yahoo.comSun Pharma to Acquire Concert Pharmaceuticals, Advancing the Potential Treatment of Alopecia AreataJanuary 19, 2023 | finance.yahoo.comUPDATE 1-India's Sun Pharma to acquire U.S.-based Concert for $576 mlnJanuary 9, 2023 | finance.yahoo.comConcert (CNCE) Moves 19.3% Higher: Will This Strength Last?December 26, 2022 | finance.yahoo.comWith 66% ownership in Concert Pharmaceuticals, Inc. (NASDAQ:CNCE), institutional investors have a lot riding on the businessDecember 5, 2022 | finance.yahoo.comBullish insiders bet US$1.1m on Concert Pharmaceuticals, Inc. (NASDAQ:CNCE)November 29, 2022 | msn.comConcert Pharmaceuticals's Return On Capital Employed InsightsNovember 21, 2022 | finance.yahoo.comConcert Pharmaceuticals Announces Presentation of Deuruxolitinib THRIVE-AA1 Phase 3 Study Results in Alopecia Areata During World Congress for Hair ResearchSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive CNCE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Concert Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address CNCE Company Calendar Last Earnings11/07/2022Today2/01/2023Next Earnings (Estimated)3/02/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CNCE CUSIPN/A CIK1367920 Webwww.concertpharma.com Phone(781) 860-0045Fax302-636-5454Employees64Year FoundedN/APrice Target and Rating Average Stock Price Forecast$19.67 High Stock Price Forecast$25.00 Low Stock Price Forecast$17.00 Forecasted Upside/Downside+135.8%Consensus RatingHold Rating Score (0-4)2.20 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($3.21) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-80,050,000.00 Net MarginsN/A Pretax Margin-300,735.69% Return on Equity-109.43% Return on Assets-76.65% Debt Debt-to-Equity RatioN/A Current Ratio9.03 Quick Ratio9.03 Sales & Book Value Annual Sales$32.58 million Price / Sales12.27 Cash FlowN/A Price / Cash FlowN/A Book Value$3.24 per share Price / Book2.57Miscellaneous Outstanding Shares47,940,000Free Float42,507,000Market Cap$399.82 million OptionableOptionable Beta0.30 Key ExecutivesRoger D. TungPresident, Chief Executive Officer & DirectorNancy StuartChief Operating OfficerMarc A. BeckerChief Financial & Accounting OfficerMitch K. GoldenbergVP-Information Technology & InfrastructureVirginia BramanVice President-Clinical DevelopmentKey CompetitorsWave Life SciencesNASDAQ:WVEVaxxinityNASDAQ:VAXXAdicet BioNASDAQ:ACETPepGenNASDAQ:PEPGHarrow HealthNASDAQ:HROWView All CompetitorsInsiders & InstitutionsIngalls & Snyder LLCSold 34,600 shares on 1/31/2023Ownership: 2.703%Nancy StuartSold 13,200 sharesTotal: $110,220.00 ($8.35/share)Jeffrey A MunsieSold 8,493 sharesTotal: $70,916.55 ($8.35/share)Assenagon Asset Management S.A.Sold 140,554 shares on 1/12/2023Ownership: 1.605%Roger D TungSold 9,240 sharesTotal: $66,897.60 ($7.24/share)View All Insider TransactionsView All Institutional Transactions CNCE Stock - Frequently Asked Questions Should I buy or sell Concert Pharmaceuticals stock right now? 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Concert Pharmaceuticals in the last year. There are currently 4 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" CNCE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CNCE, but not buy additional shares or sell existing shares. View CNCE analyst ratings or view top-rated stocks. What is Concert Pharmaceuticals' stock price forecast for 2023? 5 brokerages have issued 1 year target prices for Concert Pharmaceuticals' stock. Their CNCE share price forecasts range from $17.00 to $25.00. On average, they anticipate the company's share price to reach $19.67 in the next twelve months. This suggests a possible upside of 135.8% from the stock's current price. View analysts price targets for CNCE or view top-rated stocks among Wall Street analysts. How have CNCE shares performed in 2023? Concert Pharmaceuticals' stock was trading at $5.84 at the beginning of 2023. Since then, CNCE stock has increased by 42.8% and is now trading at $8.34. View the best growth stocks for 2023 here. When is Concert Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, March 2nd 2023. View our CNCE earnings forecast. How were Concert Pharmaceuticals' earnings last quarter? Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) announced its earnings results on Monday, November, 7th. The biotechnology company reported ($0.58) earnings per share for the quarter, beating the consensus estimate of ($0.59) by $0.01. The biotechnology company earned $0.01 million during the quarter, compared to analyst estimates of $0.33 million. What is Roger Tung's approval rating as Concert Pharmaceuticals' CEO? 1 employees have rated Concert Pharmaceuticals Chief Executive Officer Roger Tung on Glassdoor.com. Roger Tung has an approval rating of 100% among the company's employees. This puts Roger Tung in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Concert Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Concert Pharmaceuticals investors own include Gilead Sciences (GILD), Eiger BioPharmaceuticals (EIGR), Exelixis (EXEL), ACADIA Pharmaceuticals (ACAD), Nektar Therapeutics (NKTR), TG Therapeutics (TGTX), Celldex Therapeutics (CLDX), Amicus Therapeutics (FOLD), Global Blood Therapeutics (GBT) and Intel (INTC). What is Concert Pharmaceuticals' stock symbol? Concert Pharmaceuticals trades on the NASDAQ under the ticker symbol "CNCE." Who are Concert Pharmaceuticals' major shareholders? Concert Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Ingalls & Snyder LLC (2.70%), Assenagon Asset Management S.A. (1.60%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Heek Christi Van, James V Cassella, Jeffrey A Munsie, Marc A Becker, Nancy Stuart, Peter Barton Hutt, Roger D Tung and Thomas G Auchincloss. View institutional ownership trends. How do I buy shares of Concert Pharmaceuticals? Shares of CNCE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Concert Pharmaceuticals' stock price today? One share of CNCE stock can currently be purchased for approximately $8.34. How much money does Concert Pharmaceuticals make? Concert Pharmaceuticals (NASDAQ:CNCE) has a market capitalization of $399.82 million and generates $32.58 million in revenue each year. The biotechnology company earns $-80,050,000.00 in net income (profit) each year or ($3.21) on an earnings per share basis. How can I contact Concert Pharmaceuticals? Concert Pharmaceuticals' mailing address is 65 HAYDEN AVENUE SUITE 3000N, LEXINGTON MA, 02421. The official website for the company is www.concertpharma.com. The biotechnology company can be reached via phone at (781) 860-0045, via email at ir@concertpharma.com, or via fax at 302-636-5454. This page (NASDAQ:CNCE) was last updated on 2/1/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.